Biogen Inc. (ETR:IDP)
Germany
· Delayed Price · Currency is EUR 109.80
+1.05 (0.97%)
Jun 25, 2025, 11:37 AM CET
Biogen Revenue
Biogen had revenue of $2.43B USD in the quarter ending March 31, 2025, with 6.13% growth. This brings the company's revenue in the last twelve months to $9.82B, up 1.59% year-over-year. In the year 2024, Biogen had annual revenue of $9.68B, down -1.62%.
Revenue (ttm)
$9.82B
Revenue Growth
+1.59%
P/S Ratio
1.75
Revenue / Employee
$1.29M
Employees
7,605
Market Cap
15.91B EUR
Revenue Chart
* This company reports financials in USD.
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 9.68B | -159.70M | -1.62% |
| Dec 31, 2023 | 9.84B | -337.80M | -3.32% |
| Dec 31, 2022 | 10.17B | -808.30M | -7.36% |
| Dec 31, 2021 | 10.98B | -2.46B | -18.32% |
| Dec 31, 2020 | 13.44B | -933.30M | -6.49% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Siemens Healthineers AG | 23.14B |
| Merck KGaA | 21.32B |
| Bayer Aktiengesellschaft | 46.58B |
| Fresenius SE & Co. KGaA | 22.13B |
| Fresenius Medical Care AG | 19.49B |
| Sartorius Aktiengesellschaft | 3.44B |
| Carl Zeiss Meditec AG | 2.17B |
| Fielmann Group AG | 2.33B |
Biogen News
- 2 days ago - Biogen: Investors Are Missing The Bigger Picture - Seeking Alpha
- 6 days ago - 21GRAMS Wins Its First Gold Lion for Branded Pharma Campaign at Cannes Lions International Festival of Creativity - Financial Post
- 6 days ago - 20 companies in the S&P 500 whose investors have gained the greatest rewards from stock buybacks - Market Watch
- 7 days ago - Biogen Initiates Phase 3 Pediatric Study of Omaveloxolone for the Treatment of Friedreich Ataxia - GlobeNewsWire
- 7 days ago - What Does the Market Think About Biogen? - Benzinga
- 12 days ago - Biogen, UCB Take A Leap In Lupus With Promising Phase 3 Results - Benzinga
- 13 days ago - Dapirolizumab Pegol Phase 3 Data in SLE Presented at the Annual European Congress of Rheumatology (EULAR) Show Improvement in Fatigue and Reduction in Disease Activity - GlobeNewsWire
- 14 days ago - Biogen Inc. (BIIB) Presents at Goldman Sachs 46th Annual Global Healthcare Conference (Transcript) - Seeking Alpha